GlassScriptPhysician profile
Robert Lawrence Heinze
NPI 1720690837
$467.16
in general payments reported to CMS, 2019-2025
13 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $28.74 · 2024: $235 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $65.77 | 2025 | |
| Caris Mpi, INC. | $65.36 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $57.26 | 2024 | |
| Novocure INC. | $43.77 | 2025 | Optune Gio |
| Merck Sharp & Dohme LLC | $34.50 | 2024 | Welireg, Keytruda |
| Eisai INC. | $33.05 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.74 | 2023 | |
| Glaxosmithkline, LLC. | $28.44 | 2025 | Jemperli |
| Rigel Pharmaceuticals, INC. | $27.91 | 2024 | Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $26.56 | 2024 | Vanflyta |
| Genzyme Corporation | $20.15 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.71 | 2024 | Imfinzi |
| Pfizer INC. | $15.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Heinze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.